Ii-Key/HER2/neu cancer vaccine: Phase I started

Generex began an open-label Phase I trial to evaluate the AE37 vaccine in combination with a peptide vaccine in about 20 patients. The trial is being funded by the Mary Crowley Cancer Center. ...